Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: Implications for the pathogenesis and treatment of bone metastasis

Endocrine-Related Cancer

Volumn 12, Issue 2, 2005, Pages 471-482

  Normanno, N ^a   De Luca, A ^a   Aldinucci, D ^b   Maiello, M R ^a   Mancino, M ^a   D'Antonio, A ^a   De Filippi, R ^a,c   Pinto, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; GENISTEIN; GYRASE INHIBITOR; LAVENDUSTIN A; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TYRPHOSTIN;

ARTICLE; BONE MARROW CELL; BONE METASTASIS; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OSTEOCLAST; PATHOGENESIS; PHENOTYPE; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BONE NEOPLASMS; CELL DIFFERENTIATION; HUMANS; OSTEOCLASTS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STROMAL CELLS;

EID: 21244450719     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00956     Document Type: Article

References (47)

1. Albain KS, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S & Rubi S 2002 Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Research and Treatment 76 abstract S33.
2. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S & Baselga J 2003 ZD1839 (Iressa), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2 overexpressing breast cancer cells. Clinical Cancer Research 9 1274-1283.
3. Arteaga CL & Truica CI 2004 Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Seminars in Oncology 31 3-8.
4. Boyle WJ, Simonet WS & Lacey DL 2003 Osteoclast differentiation and activation. Nature 423 337-342.
5. Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP, Olson BR, Wu TL, Mitnick ME, Broadus AE & Stewart AF 1990 Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. New England Journal of Medicine 322 1106-1112.
6. Campiglio M, Locatelli A, Olgiati C, Noranno N, Somenzi G, Viganò L, Fumagalli M, Menard S & Gianni L 2004 Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. Journal of Cellular Physiology 198 259-268.
7. Clark BR & Keating A 1995 Biology of bone marrow stroma. Annals of the New York Academy of Sciences 770 70-78.
8. Corsini C, Mancuso P, Paul S, Burlini A, Martinelli G, Pruneri G & Bertolini F 2003 Stroma cells: a novel target of herceptin activity. Clinical Cancer Research 9 1820-1825.
9. D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR et al. 2002 Transforming growth factor α, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. International Journal of Oncology 21 941-948.
10. Deans RJ & Moseley AB 2000 Mesenchymal stem cells: biology and potential clinical use. Experimental Hematology 28 875-884.
11. De Luca A, Casamassimi A, Selvam MP, Losito S, Ciardiello F, Agrawal S, Salomon DS & Normanno N 1999 EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. International Journal of Cancer 80 589-594.
12. Drake MT, Baldassare JJ, McConkey CL, Gonzalez EA & Martin KJ 1994 Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-101 cells. Endocrinology 134 1733-1737.
13. Giuliani N, Colla S, Morandi F & Rizzoli V 2004 The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 89 1118-1123.
14. Horwood NJ, Elliott J, Martin TJ & Gillespie MT 1998 Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139 4743-4746.
15. Ibbotson KJ, Harrod J, Gowen M, D'Souza S, Winkler ME, Derynck R & Mundy GR 1986 Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro. PNAS 83 2228-2232.
16. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL & Rimm DL 2004 Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clinical Cancer Research 10 173-177.
17. Kodama H, Nose M, Niida S & Yamasaki A 1991 Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. Journal of Experimental Medicine 173 1291-1294.
18. Lichtner RB, Menrad A, Sommer A, Klar U & Schneider MR 2001 Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Research 61 5790-5795.
19. Lin EY, Nguyen AV, Russell RG & Pollard JW 2001 Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. Journal of Experimental Medicine 193 727-740.
20. Liu XH, Kirschenbaum A, Yao S & Levine AC 2005 Cross-talk between the IL-6 and prostaglandin E2 signalling systems results in enhancement of osteoclastogenesis through effects on the OPG/RANKL/RANK system. Endocrinology 146 1991-1998.
21. Maher MG, Sapi E, Turner B, Gumbs A, Perrotta PL, Carter D, Kacinski BM & Haffty BG 1998 Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clinical Cancer Research 4 1851-1856.
22. Mbalaviele G, Jaiswal N, Meng A, Cheng L, Van De Bos C & Thiede M 1999 Human mesenchymal stem cells promote human osteoclast differentiation from CD344-bone marrow hematopoietic progenitors. Endocrinology 140 3736-3743.
23. von Minckwitz G, Jonat W, Beckmann M, De Bois A, Kleeberg U, Kuhnie H, Kettner E, Hilfrich J, Torode J & Schneeweiss A 2003 A multicenter phase II trial to evaluate gefitinib ('Iressa', ZD1839) (500 mg/day) in patient with metastatic breast cancer after previous chemotherapy treatment. European Journal of Cancer 1 abstract S133.
24. Moasser MM, Basso A, Averbuch SD & Rosen N 2001 The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Research 61 7184-7188.
25. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF & Arteaga CL 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Research 61 8887-8895.
26. Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, Magliulo G, Tortora G, Bianco AR, Mendelsohn J et al. 1996 Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clinical Cancer Research 2 601-609.
27. Normanno N, Bianco C, De Luca A & Salomon DS 2001 The role of EGF-related peptides in tumor growth. Frontiers in Bioscience 6 d685-d707.
28. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS & Menard S 2002 Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Annals of Oncology 13 65-72.
29. Normanno N, Bianco C, De Luca A, Maiello MR & Salomon DS 2003a Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocrine-Related Cancer 10 1-22.
30. Normanno N, Maiello MR & De Luca A 2003b Epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? Journal of Cellular Physiology 194 13-19.
31. Normanno N, Maiello MR, Mancino M & De Luca A 2004 Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. Journal of Chemotherapy 16 Suppl 4 36-40.
32. Pain B, Woods CM, Saez J, Flickinger T, Raines M, Peyrol S, Moscovici C, Moscovici GM, Kung H-J, Jurdic P et al. 1991 EGF-R as a hemopoietic growth factor receptor: the c-erbB product is present in chicken erythrocytic progenitors and controls their self-renewal. Cell 65 37-46.
33. Pederson L, Winding B, Foged NT, Spelsberg TC & Oursler MJ 1999 Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Research 59 5849-5855.
34. Roodman GD 2001 Biology of osteoclast activation in cancer. Journal of Clinical Oncology 19 3562-3571.
35. Sapi E, Flick MB, Rodov S, Gilmore-Hebert M, Kelley M, Rockwell S & Kacinski BM 1996 Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Research 56 5704-5712.
36. Satomura K, Derubeis AR, Fedarko NS, Ibaraki-O'Connor K, Kuznetsov SA, Rowe DW, Young MF & Gehron Robey P 1998 Receptor tyrosine kinase expression in human bone marrow stromal cells. Journal of Cellular Physiology 177 426-438.
37. Sodek J, Chen J, Nagata T, Kasugai S, Todescan R, Li IW & Kim RH 1995 Regulation of osteopontin expression in osteoblasts. Annals of the New York Academy of Sciences 760 223-241.
38. Sohara Y, Shimada H, Minkin C, Erdreich-Epstein A, Nolta JA & DeClerck YA 2005 Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Research 65 1129-1135.
39. Symons AL 2003 Reduced growth hormone receptor immunoreactivity in osteoclasts adjacent to the erupting molar in the incisor-absent (osteopetrotic) rat. European Journal of Oral Sciences 111 503-509.
40. Takahashi N, MacDonald BR, Hon J, Winkler ME, Derynck R, Mundy GR & Roodman GD 1986 Recombinant human transforming growth factor-alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures. Journal of Clinical Investigation 78 894-898.
41. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ & Suda T 1988 Osteoblastic cells are involved in osteoclast formation. Endocrinology 123 2600-2602.
42. Tanaka S, Takahashi T, Miyazaki T, Oda H, Nakamura K, Hirai H & Kurokawa T 1998 Modulation of osteoclast function by adenovirus vector-induced epidermal growth factor receptor. Journal of Bone and Mineral Research 13 1714-1720.
43. Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P & Scholl S 1992 M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? Journal of Cellular Biochemistry 50 350-356.
44. Tashjian AH, Voelkel EF, Lazzaro M, Singer FR, Roberts AB, Derynck R, Winkler ME & Levine L 1985 Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. PNAS 82 4535-4538.
45. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ & Gillespie MT 1999 Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140 4451-4458.
46. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, Martin TJ & Suda T 1989 The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 125 1805-1813.
47. Yamagishi T, Otsuka E & Hagiwara H 2001 Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 142 3632-3637.